Mesa Verde Venture Partners

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative treatments for patients in hospital settings. The company's primary focus is on ZOLYD, an investigational injectable antibiotic designed to address serious and life-threatening infections, including those caused by multi-drug resistant gram-negative and gram-positive bacteria. Incorporated in 2013, Zavante aims to enhance patient outcomes through its novel therapeutic approaches. As of July 2018, it operates as a subsidiary of Nabriva Therapeutics plc.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Immix Biopharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer and inflammation-driven diseases. Founded in 2014 and based in Los Angeles, the company specializes in novel drug candidates aimed at treating chemotherapy and immunotherapy-resistant patients. Its portfolio includes Imx-109, a small molecule designed to enhance tumor sensitivity to various therapies; Imx-110, a nanoparticle delivery system that combines cytotoxic agents with synergistic compounds; Imx-111, a targeted version of Imx-110; and Imx-004, a humanized antibody targeting over-expressed proteins in tumors. Additionally, Immix Biopharma is engaged in the discovery of cell therapies for blood cancers and is advancing its proprietary TME Normalization Technology, which enables drug candidates to effectively target tumor microenvironments.

MatriSys Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing microbiome therapies specifically for dermatology and skin care. Headquartered in La Jolla, California, the company offers its lead product, MSB-01, a topical antimicrobial live bio therapeutic aimed at treating atopic dermatitis by restoring the necessary skin bacteria for effective host defense. In addition to therapeutics, MatriSys develops cosmetic ingredients derived from proprietary bacterial strains to address various skin conditions, including scaling, redness, and signs of aging. The company is exploring commercialization avenues across dermatology, skin care, and cosmetic sectors, with its lead therapeutic currently undergoing Phase I/II clinical trials. MatriSys aims to enhance skin health by rebalancing the skin's microbiome, promoting beneficial microbes while targeting harmful species.

NeuraLace Medical, Inc. is a technology company based in San Diego, California, founded in 2016. The company specializes in developing a hardware-based neuromodulation platform aimed at managing neuropathic pain through direct and selective stimulation of sensory nerve fibers. NeuraLace offers a non-invasive treatment system that provides significant and sustained relief from chronic nerve pain without the use of opioids. By utilizing short bursts of magnetic pulses to stimulate damaged nerves, the company's innovative approach allows for effective pain management in clinic settings, thereby reducing the risks associated with addiction to pain medications and surgical complications.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

Alastin Skincare, founded in 2015 and based in Carlsbad, California, specializes in innovative and clinically validated skincare products designed to correct, protect, and maintain healthy skin. The company produces topical skincare solutions that enhance both ablative and non-ablative rejuvenating procedures. Utilizing a proprietary blend of peptides and other scientifically-backed ingredients, Alastin's products support the skin's natural regenerative processes. Their offerings are specifically formulated for use by dermatologists and plastic surgeons, ensuring that patients receive effective treatments that promote long-term skin health. Alastin Skincare is dedicated to reawakening the skin’s youthful qualities through advanced technology and rigorous clinical testing.

Equillium Inc is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory disorders that have significant unmet medical needs. The company's leading product candidate, EQ001, is a first-in-class monoclonal antibody that specifically targets the immune checkpoint receptor CD6, which is crucial in regulating effector T cell activity associated with various immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. In addition to EQ001, Equillium's pipeline includes itolizumab, an antibody targeting the CD6-ALCAM pathway, which is undergoing Phase 3 trials for acute graft-versus-host disease and Phase 1b trials for lupus nephritis. The company is also advancing EQ101, a cytokine inhibitor aimed at IL-2, IL-9, and IL-15, which is poised to enter Phase 2 studies for alopecia areata, and EQ102, another cytokine inhibitor that targets IL-15 and IL-21, which is ready for clinical development.

Biscayne Pharmaceuticals, Inc. is a biopharmaceutical company based in Miami, Florida, focused on developing therapies that leverage growth hormone-releasing hormone (GHRH) analogs. The company is engaged in creating GHRH antagonists aimed at treating various cancers, including castrate-resistant prostate cancer, and GHRH agonists intended for cardiac repair in patients with heart disease. Additionally, Biscayne Pharmaceuticals is involved in developing drugs for refractory epilepsy and drug-resistant cancer by targeting GHRH receptors, which play a critical role in stimulating growth hormone production for tissue growth and repair. Since its incorporation in 2012, the company has aimed to provide innovative treatments for patients with challenging medical conditions.

Biscayne Neurotherapeutics is a clinical-stage biotechnology company based in Miami, Florida, focused on developing innovative therapies for challenging neurological disorders. The company is advancing its lead compound, BIS-001, aimed at treating refractory forms of epilepsy, including complex partial seizures and conditions like Dravet syndrome. BIS-001 is a synthetic version of huperzine A, an acetylcholinesterase inhibitor known for its ability to penetrate the brain effectively, offering a distinct mechanism of action. Biscayne Neurotherapeutics is supported by a seasoned executive team with a strong background in drug development, as well as a group of esteemed scientific advisors specializing in seizure and central nervous system disorders. The firm is part of the expanding biomedical sector in South Florida, positioning itself to contribute significantly to the treatment landscape for epilepsy and other neurological conditions.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Oncternal Therapeutics is a clinical-stage oncology company focused on developing innovative therapies for a range of cancers, including both rare and common types. The company has a diverse clinical pipeline featuring several promising candidates, including zilovertamab, a humanized monoclonal antibody targeting ROR1, and ONCT-216, a small molecule designed to inhibit ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a CAR-T product targeting ROR1, and ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer. By employing a variety of therapeutic strategies, including antibodies, antibody-drug conjugates, small molecules, and CAR-T technologies, Oncternal Therapeutics seeks to address significant unmet medical needs in oncology through highly targeted treatments.

Independa, Inc. is a company that develops cloud-based software solutions aimed at enhancing the well-being and social engagement of senior citizens. Its primary offerings include AnyTV Companion, a remote care platform that facilitates social interaction and provides medication reminders, appointment notifications, and monitoring capabilities. The company also offers CloudCare, an enterprise solution that integrates various modules for remote care and community involvement, along with a caregiver dashboard that simplifies monitoring and support for care recipients. Additionally, the Angela solution addresses the challenges faced by seniors wishing to maintain their independence. Independa’s software features smart reminders for events and activities, a broadcast messaging system for alerts and updates, and integrated monitoring to track health and safety. Founded in 2009 and based in San Diego, California, the company serves a range of clients, including senior living communities, hospitals, and home care organizations, and has formed a strategic partnership with LG Electronics to enhance its service offerings.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Elysium Therapeutics is a healthcare company established in 2013 and located in Danville, California. The company specializes in biotechnology and has developed innovative opioid pain relievers aimed at reducing the risks associated with oral misuse, abuse, and fatal overdose. Elysium Therapeutics' opioid medications are designed to automatically regulate opioid levels in the bloodstream, preventing them from exceeding safe limits. This approach not only minimizes the potential for addiction and adverse side effects but also enhances the ability of medical practitioners to manage pain effectively in patients requiring opioid-based treatments.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Biomatrica, Inc. is a San Diego-based company specializing in biostability technologies that preserve biological materials, including DNA, RNA, proteins, cells, and diagnostic assays, at room temperature. The company's innovative solutions leverage the principles of anhydrobiosis, a natural process that allows organisms to survive extreme conditions, enabling the stabilization and transport of biological samples without refrigeration. Biomatrica's product offerings include various stabilization solutions such as DNAstable Plus, DNAgard Saliva, and RNAgard Blood System, all designed to prevent sample degradation and reduce reliance on cold chain logistics. These products are utilized in diverse settings, including life science research, pharmaceuticals, biotechnology, and forensics. Additionally, Biomatrica provides SampleWare software, facilitating efficient sample management for laboratories. Established in 2004, the company operates as a subsidiary of Exact Sciences Corporation and serves customers through both direct sales and a global network of distributors.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Medipacs, Inc. is a company that specializes in the development of non-mechanical infusion pumps for drug delivery. Founded in 2004 and headquartered in San Diego, California, with research facilities located in Tucson, Arizona, Medipacs focuses on providing innovative solutions for the administration of various medications. Their infusion pumps are designed to deliver biologic medications, insulin, hormones, fertility drugs, anti-coagulation drugs, and pain medication. These devices enable medical professionals to effectively treat both humans and animals, particularly in managing post-surgical pain and other medical needs.